In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme acquires SangStat Medical for $596mm

Executive Summary

In a deal that will significantly add to its portfolio of immune-mediated drugs and drug candidates, Genzyme Corp. is acquiring SangStat Medical (develops, sells treatments for autoimmune disorders, immunosuppression, hematology, and cancer) for $596mm in cash, or $22.50 per share (a 51% premium to the market average).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies